1h Free Analyst Time
According to the recently published report 'Growth Hormone Secretagogue Receptor Type 1 - Drugs In Development, 2022'; Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. Speak directly to the analyst to clarify any post sales queries you may have.
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland. The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.
The report 'Growth Hormone Secretagogue Receptor Type 1 - Drugs In Development, 2022' outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 7 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Toxicology, Cardiovascular, Gastrointestinal, Genetic Disorders, Infectious Disease, Genito Urinary System And Sex Hormones, Hormonal Disorders, Metabolic Disorders, Musculoskeletal Disorders and Women's Health which include indications Cancer Anorexia-Cachexia Syndrome, Prader-Willi Syndrome (PWS), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Born Small For Gestational Age (SGA), Cachexia, Chemotherapy Effects, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Constipation, Coronavirus Disease 2019 (COVID-19), Endocrine Gland Disorders, Fatigue, Growth Hormone Deficiency, Idiopathic Short Stature, Ischemia, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Sepsis, Traumatic Brain Injury and Turner Syndrome.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
- The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
- Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
- Aeterna Zentaris Inc
- AstraZeneca Plc
- Extend Biosciences Inc
- Helsinn Group
- Lumos Pharma Inc
- Oxeia Biopharmaceuticals Inc
- Pfizer Inc
- RaQualia Pharma Inc
- Tempest Therapeutics Inc
- TheraSource LLC
- Zeria Pharmaceutical Co Ltd
- Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
- anamorelin hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AZ-12861903 - Drug Profile
- Product Description
- Mechanism Of Action
- EXT-405 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EXT-418 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- HM-01 - Drug Profile
- Product Description
- Mechanism Of Action
- HM-04 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ibutamoren mesylate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- livoletide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- macimorelin acetate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OXE-103 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PF-05190457 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RQ-00433412 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Agonize GHSR for Cachexia - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Z-505 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
- Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
- Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
- Featured News & Press Releases
- May 25, 2022: Aeterna Zentaris’ licensing partner, Consilient Health announces European launch of Ghryvelin (macimorelin) for diagnosing adult growth hormone deficiency
- May 05, 2022: Lumos Pharma announces a clinical collaboration with Massachusetts General Hospital (MGH) to evaluate oral LUM-201 in nonalcoholic fatty liver disease (NAFLD) in a phase 2 investigator-initiated trial
- Apr 11, 2022: Lumos Pharma reaches 50% randomization milestone in phase 2 OraGrowtH210 trial evaluating oral LUM-201 in PGHD
- Mar 21, 2022: Aeterna Zentaris provides update on ongoing pivotal phase 3 DETECT-Trial for the diagnosis of childhood-onset growth hormone deficiency
- Jul 20, 2021: Lumos Pharma announces clinical updates
- Jun 28, 2021: Lumos Pharma announces OraGrowtH212 trial of LUM-201 in PGHD is open for enrollment
- Jun 03, 2021: Aeterna Zentaris announces final settlement of previously disclosed class-action lawsuit
- May 17, 2021: Aeterna Zentaris announces the start of preclinical development of Macimorelin at The University of Queensland as a potential new treatment option for patients with amyotrophic lateral sclerosis (ALS, Lou Gehrig’s Disease)
- May 13, 2021: Aeterna Zentaris commences pivotal phase 3 DETECT-trial for the diagnosis of childhood-onset growth hormone deficiency
- Apr 27, 2021: Newly released data on three PGHD patients treated with LUM-201 in prior phase 2 study to be presented in Lumos Pharma Key Opinion Leader Webinar
- Apr 21, 2021: Launch of Adlumiz (anamorelin), a Ghrelin Receptor Agonist in Japan
- Apr 14, 2021: Lumos Pharma to host key opinion leader event on LUM-201 for the treatment of pediatric growth hormone deficiency
- Mar 20, 2021: Data presented at ENDO 2021 differentiate LUM-201 from standard growth hormone secretagogues and further support LUM-201’s potential as a therapeutic for pediatric growth hormone deficiency
- Mar 04, 2021: Data supporting use of predictive enrichment markers for Lumos Pharma’s LUM-201 therapy in clinical trials for moderate PGHD published in Journal of the Endocrine Society
- Mar 02, 2021: Lumos Pharma to present poster demonstrating greater GH response to LUM-201 than to standard GH secretagogues in PGHD at the Endocrine Society (ENDO) 2021 annual meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Aeterna Zentaris Inc, 2022
- Pipeline by AstraZeneca Plc, 2022
- Pipeline by Extend Biosciences Inc, 2022
- Pipeline by Helsinn Group, 2022
- Pipeline by Lumos Pharma Inc, 2022
- Pipeline by Oxeia Biopharmaceuticals Inc, 2022
- Pipeline by Pfizer Inc, 2022
- Pipeline by RaQualia Pharma Inc, 2022
- Pipeline by Tempest Therapeutics Inc, 2022
- Pipeline by TheraSource LLC, 2022
- Pipeline by Zeria Pharmaceutical Co Ltd, 2022
- Dormant Products, 2022
- Dormant Products, 2022 (Contd..1)
- Dormant Products, 2022 (Contd..2)
- Discontinued Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aeterna Zentaris Inc
- AstraZeneca Plc
- Extend Biosciences Inc
- Helsinn Group
- Lumos Pharma Inc
- Oxeia Biopharmaceuticals Inc
- Pfizer Inc
- RaQualia Pharma Inc
- Tempest Therapeutics Inc
- TheraSource LLC
- Zeria Pharmaceutical Co Ltd
